美国 · 平台与数据 · The Motley Fool

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

来源：The Motley Fool · 美国 1 小时前

Viking aims to enter the weight loss drug market.

在 The Motley Fool 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

推荐阅读

Trainline (LON:TRN) Given Buy Rating at Shore Capital Group

Natural Resource Partners declares $2.34 dividend

Tesla and SpaceX shares slide as Musk’s political push falls flat

Earnings call transcript: Lupin beats q2 2027 estimates, but margins soften

Treasury yields fall after Democrats win House and Senate majorities

Best Stocks Under $5